Outcomes of vascular closure devices for femoral venous hemostasis following catheter ablation of atrial fibrillation
Journal of Cardiovascular Electrophysiology · 2024
DOI: 10.1111/jce.16345 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2024. Verfasst von Mark T Mills und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Liverpool Heart & Chest Hospital, Liverpool, UK. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Femoral Vein, Hemostatic Techniques. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Access site complications remain common following atrial fibrillation (AF) catheter ablation. Femoral vascular closure devices (VCDs) reduce time to hemostasis compared with manual compression, although large‐scale data comparing clinical outcomes between the two approaches are lacking.
Methods
Two cohorts of patients undergoing AF ablation were identified from 36 healthcare organizations using a global federated research network (TriNetX): those receiving a VCD for femoral hemostasis, and those not receiving a VCD. A 1:1 propensity score matching (PSM) model based on baseline characteristics was used to create two comparable cohorts. The primary outcome was a composite of all‐cause mortality, vascular complications, bleeding events, and need for blood transfusion. Outcomes were assessed during early (within 7 days of ablation) and extended follow‐up (within 8–30 days of ablation).
Results
After PSM, 28 872 patients were included (14 436 in each cohort). The primary composite outcome occurred less frequently in the VCD cohort during early (1.97% vs. 2.60%, odds ratio (OR) 0.76, 95% confidence interval (CI) 0.65–0.88; p < .001) and extended follow‐up (1.15% vs. 1.43%, OR 0.80, 95% CI 0.65–0.98; p = .032). This was driven by a lower rate of vascular complications during early follow‐up in the VCD cohort (0.83% vs. 1.26%, OR 0.66, 95% CI 0.52–0.83; p < .001), and fewer bleeding events during early (0.90% vs. 1.23%, OR 0.73, 95% CI 0.58–0.92; p = .007) and extended follow‐up (0.36% vs. 0.59%, OR 0.61, 95% CI 0.43–0.86; p = .005).
Conclusion
Following AF ablation, femoral venous hemostasis with a VCD was associated with reduced complications compared with hemostasis without a VCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Liverpool Heart & Chest Hospital, Liverpool, UK.
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
- Department of Clinical Medicine, Danish Center for Health Services Research, Aalborg University, Aalborg, Denmark.
ORCID-Profile: Peter Calvert, Vishal Luther, Dhiraj Gupta
Zitieren
APA
Mills, M. T., Calvert, P., Lip, G. Y. H., Luther, V., & Gupta, D. (2024). Outcomes of vascular closure devices for femoral venous hemostasis following catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.16345
Vancouver
Mills MT, Calvert P, Lip GYH, Luther V, Gupta D. Outcomes of vascular closure devices for femoral venous hemostasis following catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology. 2024. doi:10.1111/jce.16345
BibTeX
@article{Mills2024,
author = {Mills, Mark T and Calvert, Peter and Lip, Gregory Y H and Luther, Vishal and Gupta, Dhiraj},
title = {Outcomes of vascular closure devices for femoral venous hemostasis following catheter ablation of atrial fibrillation},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2024},
doi = {10.1111/jce.16345}
}
EUVIMED